Positron emission tomography (PET), in combination with 11 C-raclopride, was used to examine the effects of phencyclidine (PCP) on dopamine (DA) in the primate striatum. In addition, we explored the hypotheses that GABAergic pathways as well as molecular targets beyond the N-methyl-D-aspartate (NMDA) receptor complex (ie dopamine transporter proteins, DAT) contribute to PCP's effects. In the first series of experiments, 11 C-raclopride was administered at baseline and 30 min following intravenous PCP administration. In the second series of studies, g-vinyl GABA (GVG) was used to assess whether enhanced GABAergic tone altered NMDA antagonistinduced changes in DA. Animals received an initial PET scan followed by pretreatment with GVG (300 mg/kg), then PCP 30 min prior to a second scan. Finally, we explored the possible contributions of DAT blockade to PCP-induced increases in DA. By examining 11 Ccocaine binding a paradigm in which PCP was coadministered with the radiotracer, we assessed the direct competition between these two compounds for the DAT. At 0.1, 0.5, and 1.0 mg/kg, PCP decreased 11 C-raclopride binding by 2.1, 14.9 7 2.2 and 8.18 7 1.1%, respectively. These effects were completely attenuated by GVG (3.38 7 3.1% decrease in 11 C-raclopride binding). Finally, PCP (0.5 mg/ kg) decreased 11 C-cocaine binding by 25.5 7 4.3%, while at 1.0 mg/kg this decrease was 13.5%, consistent with a competitive interaction at the DAT. These results suggest that PCP may be exerting some direct effects through the DAT and that GABA partially modulates NMDA-antagonist-induced increases in striatal DA.
INTRODUCTION
Phencyclidine (PCP), an N-methyl-D-aspartate (NMDA) receptor antagonist, was developed more than four decades ago as an intravenous anesthetic. Its use was discontinued when it became apparent that it was addictive and frequently produced psychological dependence, compulsive drug-seeking behavior, and profound psychotic episodes. According to the National Household Survey on Drug Abuse (NHSDA), 3.2% of the population aged 12 years and older have used PCP at least once, and the abuse of its cogener and popular 'club drug', ketamine, has increased dramatically since 1999. While PCP and ketamine are readily self-administered by animals (Rodefer and Carroll, 1999) , the role and extent of reward-related dopaminergic processes in these behaviors remain to be established. This becomes even more critical with respect to the similarity between PCP-induced psychoses and schizophrenic syndromes that are partially ameliorated by dopamine (DA) antagonist drugs.
Rapid increases in striatal DA appear to represent an integral component of the self-reported 'high', associated with psychostimulants (Volkow et al, 1999) . These increases may be achieved directly through interactions with DA releasing or reuptake mechanisms, or indirectly through interactions with other functionally linked neurotransmitter systems. For example, the initial molecular targets of most drugs of abuse, including the opiates, nicotine, and PCP are not dopaminergic. In fact, all these compounds exert their effects through multiple efferent pathways that originate from sites distal to the mesolimbic DA system. With respect to PCP and ketamine, the mechanisms that connect NMDA receptor blockade to striatal DA systems remain undetermined. Some evidence indicates that like the opiates, antagonism of NMDA receptors may prevent the excitation of inhibitory GABAergic neurons that normally modulate these pathways (Grunze et al, 1996; Li et al, 2002) . This disinhibition may contribute to the reward-related DA response in the striatum and other mesolimbic and mesocortical brain regions, and may be one mechanism involved in NMDA antagonist-induced psychoses (Olney and Farber, 1995) . Alternatively, PCP and/or ketamine may stimulate striatal DA through a direct interaction between glutamatergic and dopaminergic neurons (Adams and Moghaddam, 1998) . Further complicating possible interactions with DA systems is PCP's relatively potent affinity for the dopamine transporter (DAT) site; an effect not shared by its congener, MK-801 (Johnson and Snell, 1985; Maurice et al, 1991) . Nevertheless, since the affinity of PCP for the NMDA receptor is so much greater than its affinity for the DAT, it has been suggested that blockade of transporter proteins is unlikely to contribute significantly to either its behavioral or neurochemical response (Carlezon and Wise, 1996) . Moreover, the involvement of DA systems in the rewarding or psychotomimetic properties of PCP has yet to be unequivocally established, and recent studies suggest that NMDA antagonists may exert their effects in the absence of any dopaminergic contribution (Adams et al, 2002; Kegeles et al, 2002) .
Therefore, at the most fundamental level, it becomes critical to characterize the dopaminergic response to specific NMDA antagonists. In doing so, novel experimental strategies can begin to unravel the putative mechanisms involved in this response. Positron emission tomography (PET) provides the unique opportunity to observe changes in synaptic DA noninvasively by measuring changes in radiotracer binding. Our laboratory and others have used this technique to provide evidence that ketamine significantly increases synaptic DA transmission (Breier et al, 1998; Smith et al, 1998; Tsukada et al, 2000; Vollenweider et al, 2000) . We have also successfully employed this approach to characterize functional interactions between cholinergic, GABAergic, serotonergic, and dopaminergic neurotransmitter systems (Dewey et al, , 1992 (Dewey et al, , 1993a . In the present study, we used 11 C-raclopride in combination with PET to study the effect of a range of PCP doses on synaptic DA. In addition, we examined the effects of increased GABAergic inhibition on this response. Finally, we used 11 C-cocaine to define more accurately contributions of DAT blockade to the possible DA-enhancing effects of PCP.
MATERIALS AND METHODS

Baboon PET Studies
Adult female baboons (Papio anubis, 14.5-18 kg) were prepared for PET scanning as detailed previously (Dewey et al, 1992) . Animals were initially immobilized with Saffan (B10 ml) and subsequently maintained on gas anesthesia using isoflurane, nitrous oxide, and oxygen for the duration of the PET study.
11
C-raclopride was synthesized as previously described (specific activity, 500-900 mCi/mmol). In all studies, dynamic PET scanning commenced simultaneously with 11 C-raclopride injection and was performed for 60 min in a Siemens HR+using the following scanning protocol: 10 scans with a 1-min interval followed by 10 scans with a 5-min interval. For 11 C-cocaine (synthesized according to Fowler et al, 1989) , the scanning protocol was four scans with a 0.5-min interval followed by four scans with a 1.0-min interval, four scans with a 2.0-min interval, four scans with a 5.0-min interval, and four scans with a 7.0-min interval. 
Pharmacologic Treatment Strategy
In the first series of studies, phencyclidine hydrochloride (PCP, Sigma Pharmaceuticals) was administered as an intravenous bolus injection at 0.1, 0.5, and 1.0 mg/kg 30 min prior to the second 11 C-raclopride scan. To potentiate whole-brain GABAergic transmission, g-vinyl GABA (GVG, a specific suicide inhibitor of GABA amino-transferase, GABA-T; Jung et al, 1977) was administered 2.5 h prior to PCP administration. The inhibition of GABA-T has been shown to elevate GABA concentrations significantly in the human CNS, maximally between 2 and 4 h following parenteral administration (Palfreyman et al, 1981) .
In the next series of studies, animals received a baseline 11 C-cocaine scan followed by PCP (0.5 and 1.0 mg/kg) given 30 min prior to or coadministered with the second 11 Ccocaine injection. For the coadministration studies, a solution of PCP was prepared prior to the second radiotracer delivery and injected into the vial containing the 11 Ccocaine, immediately prior to intravenous injection and subsequent scanning.
Design of Studies
All scanning protocols involved two 11 C-raclopride or 11 Ccocaine injections, while each animal remained in the tomograph. The first scan served as the baseline for the second, postchallenge scan.
We previously established the reproducibility of 11 Craclopride binding as well as the effects of GVG on this binding in papio anubis baboons, using a test/retest experimental protocol in which each animal (n ¼ 7) served as its own control (Dewey et al, 1992) . PCP was administered 30 min prior to the second 11 C-raclopride scan, according to a time course established by Blin et al (1991) . These studies were performed using 0.1 mg/kg (n ¼ 1), 0.5 mg/kg (n ¼ 6), and 1.0 mg/kg (n ¼ 3) PCP. In a separate group of animals, GVG was administered intravenously (300 mg/kg in 4.0 ml over 3 min) immediately following completion of the first dynamic scan (n ¼ 4). After 2.5 h, PCP was administered 30 min prior to the second 11 C-raclopride scan. Finally, we examined the time course and effects of PCP on 11 C-cocaine binding by administering PCP (1.0 mg/kg) either 30 min prior to the second 11 C-cocaine scan or simultaneously (0.5 or 1.0 mg/kg) with 11 C-cocaine.
Region of Interest Selection
Regions of interest (ROI) for the corpus striatum were drawn directly on the PET image to encompass the entire structure on every slice upon which it appeared and where appropriate in size for the resolution of the tomograph. This multiplanar method of ROI selection reduces differences that may arise due to movement of the animal within the gantry during the scanning interval . ROIs were then copied directly from the first scan to the appropriate slices of the second. Further analysis was targeted at separating the dorsal and ventral striata according to methods described by Drevets et al (1999) . Cerebellar ROIs were drawn at the level of the vermis and included both cortical gray and white matter.
Data Analysis
Receptor availability as a function of changes in endogenous DA concentration was analyzed using a graphical technique specifically designed for reversible systems. This technique gives a linear function of the free receptor concentration known as the distribution volume (DV; Logan et al, 1990) . The ratio of striatal to cerebellar distribution volumes (DVR) is less sensitive to noise than the individual kinetic parameters, which often have large standard errors associated with their determination. In addition, the DVR is independent of blood flow, since blood flow terms appear in the numerator and denominator and subsequently cancel out (K 1 /k 2 ; Logan et al, 1994) . The use of the DVR is also supported by the observations that the striatum and cerebellum have comparable amounts of nonspecific binding (Farde et al, 1989) and that our preliminary studies demonstrated that PCP did not alter the cerebellar DV in a systematic manner (either increase or decrease) in excess of the test-retest variability for this region.
We quantified 11 C-cocaine binding using a similar tracer kinetic modeling approach applied to differences in the availability of striatal transport proteins between test/retest animals or those pretreated with PCP. One factor that might affect estimates of binding site densities based on PET measurements is variability in the local concentration of DA; however, recent studies have demonstrated that 11 Ccocaine is relatively insensitive to changes in endogenous DA (Gatley et al, 1995) , consistent with in vitro competition experiments with DA, suggesting that cocaine binds about 100 times more strongly at the DAT than DA (Madras et al, 1989) . However, both 11 C-raclopride and 11 C-cocaine possess a rapid dissociation constant (Logan et al, 1990) . This facilitates a similar fundamental kinetic modeling approach, so as with 11 C-raclopride, DVRs for striatum and cerebellum can be related to the 11 C-cocaine-binding site kinetic parameters by the ratio of striatal to cerebellar DVs.
Statistical Analysis
The statistical analysis was designed to test whether there was a difference in radiotracer binding between the dorsal and ventral tiers of the striatum and then whether this difference was a function of drug treatment prior to the second scan. Thus, differences between dorsal and ventral striata were evaluated with a one-way analysis of variance (ANOVA) across baseline scans and both baseline and challenge data were then subjected to a two-way repeated measures ANOVA with treatment group and region (dorsal vs ventral) as factors. Where appropriate, post hoc significance testing was performed with a Bonferroni t-test. Finally, to reduce the number of comparisons and to take into account the baseline condition, difference scores were computed for the striatum, cerebellum, and the striatum to cerebellum ratio, using the formula (DVR Baseline Scan À DVR Challenge Scan )/DVR Baseline Scan . The difference scores were subjected to a one-way ANOVA, with treatment group as a between-subject factor. The mean time-activity of 11 C-raclopride (corrected for the injected dose) was also subjected to a repeated measures ANOVA to address specific changes in radiotracer washout between animals.
RESULTS
C-Raclopride PET Scans
Immediately following administration of 11 C-raclopride, radioactivity accumulated in the corpus striatum bilaterally. In the cerebellum, radioactivity began to clear within the first 3 min and reached 50% of the peak within 5 min. Striatal radioactivity continued to accumulate and reached a peak value within 5 min and cleared to 50% of the peak within 25 min. In terms of the DVR, the test/retest reproducibility was determined to be 2.6% from the first to the second 11 C-raclopride scan ( Craclopride binding from baseline to postchallenge in animals treated with 0.5 mg/kg PCP (DVR Baseline and DVR Challenge ¼ 3.52 7 0.09 and 3.00 7 0.12, respectively; t ¼ 8.80, po0.001) and 1.0 mg/kg PCP (DVR Baseline and DVR Challenge ¼ 3.14 7 0.15 and 2.88 7 0.16, respectively; t ¼ 3.033, po0.01). These decreases appeared to be greater in the ventral compared to the dorsal striatum. There were no significant differences in 11 C-raclopride binding from baseline to challenge scans when animals were given the lowest dose of PCP (0.1 mg/kg; DVR Baseline and DVR Challenge ¼ 3.65 and 3.57, respectively; t ¼ 0.546, p ¼ 0.594) or GVG prior to 0.5 mg/kg PCP (DVR Baseline and DVR Challenge ¼ 3.25 7 0.29 and 3.14 7 0.21, respectively; t ¼ 1.501, p ¼ 0.157). None of the doses of PCP or GVG prior to PCP altered cerebellar radioactivity, the systemic rate of labeled raclopride metabolism, or the metabolite corrected plasma input function. Figure 1 illustrates the graphical analysis applied to data from two separate animals, one given PCP alone (Figure 1a ) and the other pretreated with GVG and PCP (Figure 1b) .
Figures 2 and 3 demonstrate the temporal binding parameters of 11 C-raclopride. We observed significant differences across time points between the baseline and postchallenge scans in the group given PCP alone (Figure 2 ), but not in the group pretreated with GVG and then PCP (Figure 3) . In primates who received only PCP, a repeated measures ANOVA indicated that significant differences between baseline and postchallenge 11 C-raclopride scans correlated with times of peak radioactivity ( C-raclopride time-activity data from striatal ROIs in (a) one primate given a 0.5 mg/kg PCP challenge and (b) a primate pretreated with GVG (300 mg/kg) followed by the same PCP challenge. ROI(T) refers to radioactivity in the striatum at time T. C p (t) is the plasma radioactivity concentration corrected for metabolites. Figure 2 Time-activity data from striatum and cerebellum ROIs from five PET studies where primates were given a PCP challenge (0.5 mg/kg) prior to the second 11 C-raclopride scan. All points on the graph are corrected for the presence of labeled raclopride metabolites, and represent mean 7 standard error for all three animals. Univariate repeated measures ANOVA indicates a significant difference between baseline and postchallenge (PCP alone) conditions at a given time, T (*po0.05).
significant between-group differences in striatal activity from baseline to postchallenge (F ¼ 45.60, po0.0001), but not in cerebellar activity (F ¼ 2.71, p ¼ 0.108).
C-Cocaine PET Scans
There was a marked accumulation of 11 C-cocaine in striatal regions, whereas levels of radioactivity in the cerebellum were much lower in all groups. Analysis of radioactivitycorrected time-activity curves indicates that the striatal accumulation of 11 C-cocaine peaked around 5.0 min, and rapidly declined. The test/retest reliability of 11 C-cocaine is given in Table 1 . Regional analysis of all baseline 11 Ccocaine specific binding in the dorsal vs ventral striata indicated that there were no regional effects (n ¼ 8, DVR 7 SEM ¼ 2.13 7 0.16 vs 2.3 7 0.2, respectively; F [1, 14] ¼ 0.679, p ¼ 0.424). However, there appears to be a significant interaction between treatment group and DVR when the regions were combined, such that a significant reduction in 
DISCUSSION
In the present study, we used PET to explore the hypothesis that targets outside the NMDA receptor complex contribute to PCP-induced decreases in 11 C-raclopride binding. First, we provide evidence that GABAergic systems are involved in this response, since it can be attenuated with GVG pretreatment. Second, our data demonstrate a potent interaction between PCP and the 11 C-cocaine-binding site in the living primate, which may contribute to decreases in striatal 11 C-raclopride binding by preventing reuptake of synaptic DA, in addition to blocking norepinephrine and serotonin reuptake. Together, these experiments contribute to a growing body of literature suggesting that NMDA antagonist mediated changes in striatal DA may be partially mediated by GABAergic systems, and also by blockade of monoamine transporters.
PET studies in humans demonstrated that ketamine significantly reduced the binding of 11 C-raclopride, consistent with increased competition from synaptic DA (Breier et al, 1998; Smith et al, 1998; Vollenweider et al, 2000) . However, recent microdialysis findings suggest that PCP may not increase striatal ECF DA in nonhuman primates (Adams et al, 2002) , and that ketamine may not alter 11 Craclopride binding in humans (Kegeles et al, 2002) . Studies by Tsukada et al (2000) may present some resolution to this problem. They combined microdialysis and PET measures in conscious monkeys to demonstrate that ketamine decreased 11 C-raclopride binding, but did not affect extracellular DA. Further, Tsukada et al (2001) attribute ketamine's lack of effect on extracellular systems to an increased efficacy of DAT sites, while our data suggest that PCP specifically, is a more potent blocker of these proteins than was previously thought. Thus, microdialysis measures of increases in extracellular DA in response to PCP might reflect spillover secondary to monoamine transporter blockade at higher doses (Schiffer et al, 2001a) , while lower doses of PCP may be absent from this effect. In fact, recent findings using MK-801 have provided evidence that this drug increases the availability of DAT sites (Nakano et al, 1998; Page et al, 2000; Schiffer et al, 2001b; Kagawa et al, 2002) . Taken together, it appears that individual NMDA antagonists might produce compound-specific effects on striatal dopaminergic systems as a function of their affinity for targets outside the NMDA receptor complex. In agreement with this, recent in vitro data also suggest that ketamine and to a lesser extent PCP, compete directly with 3 H-raclopride binding at the high affinity D 2 receptor site Seeman, 2001, 2002) . Therefore, it appears that there may be a multitude of mechanisms by which PCP increases extracellular DA or alters 11 C-raclopride binding. If NMDA receptor antagonism diminishes GABA neuron firing (Hondo et al, 1995) , then systemically increasing GABAergic inhibition (via GABA A or GABA B receptor agonists) should have little consequence. In fact, our previous in vivo microdialysis results in freely moving animals demonstrated that increased GABAergic activity produced a preferential inhibition of cortical over subcortical DA release (Schiffer et al, 2001a) . Similarly, local application of specific GABA receptor agonists (muscimol, baclofen, or bicuculline) in cortical (Yonezawa et al, 1998) or subcortical (Westerink et al, 1996) areas produced a Figure 3 Time-activity data from striatum and cerebellum ROIs from four PET studies where primates were pretreated with GVG (300 mg/kg) prior to a PCP challenge (0.5 mg/kg) before the second 11 C-raclopride scan. All points are corrected for the presence of labeled raclopride metabolites, and represent mean 7 standard error for all five animals. Univariate repeated measures ANOVA indicates a significant difference between baseline and postchallenge (GVG+PCP) conditions at a given time, T (*po0.05). similar inhibition of the same system. Consistent with these studies, electrophysiological measures in the hippocampus suggest that disinhibition of GABAergic regulatory processes by NMDA antagonists may be a primary mechanism associated with NMDA antagonist-induced stimulation (Grunze et al, 1996) . Combined with behavioral evidence indicating that GVG and other GABA agonists can diminish some of the stereotypies associated with PCP (Seiler and Grauffel, 1992 ), it appears that at least some, if not all, of the GABAergic inhibitory control is spared from the effects of NMDA receptor antagonism.
It is possible that these 'spared' GABAergic effects are also a function of the dose of PCP, and may be related to its additional molecular targets. We demonstrate a significant, reproducible decrease in 11 C-cocaine binding, consistent with direct competition for the DAT and perhaps a shared mechanism. Interestingly, this effect was less pronounced at the highest and lowest doses of PCP. This provides one explanation for previous findings in which doses below those used here did not increase striatal extracellular DA, nor did they markedly influence nomifensine-induced DA overflow (Adams et al, 2002) . The present PET studies suggest an inverted U-shaped dose-response curve for both inhibiting 11 C-raclopride and 11 C-cocaine binding, where 0.5 mg/kg PCP produced a greater inhibition of both radiotracers than 1.0 mg/kg. Thus, doses of 1.0 mg/kg PCP may exceed the psychotomimetic and addictive effects of PCP, and our results at these doses represent those that might occur during anesthesia or during preanesthetic ataxic states associated with PCP. Consistent with this latter hypothesis, we did not have to alter our anesthesia at any time following PCP administration and there were no changes in vital signs following its administration.
Direct competition with transporter proteins does not completely explain the present finding that increasing GABAergic tone attenuates PCP-induced decreases in 11 Craclopride binding. For example, in the present study, while GVG attenuated PCP-induced decreases in 11 C-raclopride binding, it totally abolished cocaine-induced decreases in 11 C-raclopride binding . However, effects reported with cocaine may also involve other neurotransmitter systems including serotonin, acetylcholine, and norepinephrine. Consistent with this notion of multitransmitter effects, a component of the PCP-induced effects may be related to NMDA receptor modulation. In fact, comparisons of PCP and MK-801, which have little or no affinity for the DAT (Maurice et al, 1991) , indicate that both drugs possess rewarding and reinforcing properties (Willins, 1993) , even though there is little support for an excitatory effect of MK-801 on DA activity (Mele et al, 1998) . Further, if the present reductions in 11 C-raclopride binding were due to a direct competition for D 2 receptor sites Seeman, 2001, 2002) , then it is unlikely that a priori increases in GABAergic tone would influence this effect. Thus, it appears that PCP-induced decreases in 11 Craclopride binding are related to a combination of direct stimulation from glutamatergic spillover (Adams and Moghaddam, 1998) and DAT blockade itself (Schiffer et al, 2001a) and that like cocaine, these decreases are susceptible to partial modulation by GABAergic systems.
Finally, these studies continue to support our premise that moderate affinity radiotracers provide a dynamic measure of competition from synaptic DA, which appear sensitive to pharmacologic manipulations of dopaminergic, serotonergic, GABAergic, cholinergic, and now glutamatergic systems (Dewey et al, 1993b Schloesser et al, 1996) . PET therefore provides a unique opportunity to observe and compare the cascade of neurochemical events produced by drugs that appear to have similar initial targets. These data may have implications for the development of unique therapeutic strategies targeted at specific neurotransmitter systems currently implicated in schizophrenia and addiction.
